Literature DB >> 31493448

Impact of drug particle shape on permeability and cellular uptake in the lung.

S Zellnitz1, L Zellnitz1, M T Müller1, C Meindl2, H Schröttner3, E Fröhlich4.   

Abstract

The generation of inhalable sized particles (1-5 μm) usually involves a particle-processing step; most commonly milling but spray drying has shown to be a suitable alternative. Besides particle size, processing may affect other particle properties, like shape and solid-state. For example, spray drying of salbutamol sulphate leads to spherical shaped predominantly amorphous particles whereas jet milling frequently maintains the irregular shape and the crystallinity of the raw material. The aim of the present study was to investigate whether particle properties, especially shape, change the biological action of the inhaled particles as well. Therefore, highly water soluble salbutamol sulphate and poorly water soluble budesonide were compared regarding dissolution, permeation and preferential uptake by epithelial cells compared to macrophages after jet milling and spray drying. For both drugs the spray dried, predominantly amorphous, particles resulted in lower respirable fractions, but higher permeability and cell uptake rates compared to the needle shaped, predominantly crystalline particles. The distinct particle properties did not affect the dissolution behaviour of salbutamol sulphate. In turn for drugs with lower solubility (budesonide), spray dried particles dissolved slower compared to jet milled particles. Preferential uptake by macrophages was higher for spray dried particles, suggesting that processing may improve targeted delivery. The comparison between murine cell lines and human monocyte derived macrophages primary cells showed similar trends in rate and preference of particle uptake.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Budesonide; Cellular uptake; Dissolution; Dry powder inhalation; Macrophages; Particle shape; Salbutamol sulphate

Mesh:

Substances:

Year:  2019        PMID: 31493448     DOI: 10.1016/j.ejps.2019.105065

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  6 in total

Review 1.  Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review.

Authors:  You Xu; Hongmei Liu; Lei Song
Journal:  J Nanobiotechnology       Date:  2020-10-19       Impact factor: 10.435

2.  Understanding Carrier Performance in Low-Dose Dry Powder Inhalation: An In Vitro-In Silico Approach.

Authors:  Joana T Pinto; Inês Cachola; João F Pinto; Amrit Paudel
Journal:  Pharmaceutics       Date:  2021-02-24       Impact factor: 6.321

3.  Drug delivery of 6-bromoindirubin-3'-glycerol-oxime ether employing poly(D,L-lactide-co-glycolide)-based nanoencapsulation techniques with sustainable solvents.

Authors:  Anna Czapka; Christian Grune; Patrick Schädel; Vivien Bachmann; Karl Scheuer; Michael Dirauf; Christine Weber; Alexios-Leandros Skaltsounis; Klaus D Jandt; Ulrich S Schubert; Dagmar Fischer; Oliver Werz
Journal:  J Nanobiotechnology       Date:  2022-01-04       Impact factor: 10.435

4.  Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19.

Authors:  Jingjing Li; Kai Zhang; Di Wu; Lianjie Ren; Xinyu Chu; Chao Qin; Xiaopeng Han; Taijun Hang; Yungen Xu; Lei Yang; Lifang Yin
Journal:  Asian J Pharm Sci       Date:  2021-10-21       Impact factor: 6.598

Review 5.  Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence.

Authors:  Samar Zuhair Alshawwa; Abeer Ahmed Kassem; Ragwa Mohamed Farid; Shaimaa Khamis Mostafa; Gihan Salah Labib
Journal:  Pharmaceutics       Date:  2022-04-18       Impact factor: 6.525

6.  Development of a Spray-Dried Formulation of Peptide-DNA Nanoparticles into a Dry Powder for Pulmonary Delivery Using Factorial Design.

Authors:  Miftakul Munir; Vicky L Kett; Nicholas J Dunne; Helen O McCarthy
Journal:  Pharm Res       Date:  2022-04-19       Impact factor: 4.580

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.